newsfilter
← Latest News
PR Newswire·

Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders

SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Tryp Therapeutics (CSE:TRYP, OTCQB:TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has re